I-10 Lars Lindbom Addressing variability and uncertainty in pooled pre-clinical data improved the quality of compound selection of a gamma secretase modulator in Alzheimer’s Disease Wednesday 10:15-11:45 |
I-16 Arianna Madrid Aispuro A Systematic Approach to PKPD Model Development to describe Sleep Effects of Compounds with Different Mechanisms of Action Using Semi-Mechanistic Markov Chain Models Wednesday 10:15-11:45 |
I-21 Amelie Marsot Thiopental and esomeprazole in critically ill patients: Drug interaction. Wednesday 10:15-11:45 |
I-49 Klas Petersson Simultaneous modeling of prolactin data following administration of seven D2–receptor antagonists in rats; Model-based in vitro – rat – human scaling Wednesday 10:15-11:45 |
I-52 Venkatesh Pilla Reddy Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety Wednesday 10:15-11:45 |
I-54 Bart Ploeger Investigation of a Data Transformation Procedure to Improve Identifiability of Efficacy and Potency: Application to Continuous Elevated Plus-Maze Data in Rats Wednesday 10:15-11:45 |
I-69 Yu-Yuan Chiu Dose-Response Model of Lurasidone Treatment in Schizophrenia Wednesday 10:15-11:45 |
II-09 Rik Schoemaker Modelling and simulation of spontaneously reported adverse events after administration of lacosamide Wednesday 15:10-16:40 |
II-12 Kwang-Hee Shin Population Pharmacokinetics and Pharmacodynamics of Escitalopram in Healthy Volunteers Wednesday 15:10-16:40 |
II-18 Nelleke Snelder Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers, AZD6765 and Ketamine, in an Animal Model of Depression Using Count Data Wednesday 15:10-16:40 |
II-30 Stina Syvänen P-glycoprotein alterations at the blood-brain barrier influences [11C]flumazenil brain concentrations but does not interfere with estimation of GABAA receptor density in a rodent model of epilepsy Wednesday 15:10-16:40 |
II-46 Nieves Velez de Mendizabal Discrete distribution models for relapsing-remitting dynamics observed in Multiple Sclerosis Wednesday 15:10-16:40 |
II-50 Sandra Visser MModel-based meta analysis of -secretase inhibitor data; has A production inhibition been adequately tested as therapeutic approach in mild AD? Wednesday 15:10-16:40 |
II-53 Carin Wallsten Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, using Mouse EEG Data Wednesday 15:10-16:40 |
II-68 Parviz Ghahramani Population Pharmacokinetic Model for Cariprazine and its Major Metabolites in Patients with Acute Exacerbation of Schizophrenia Wednesday 15:10-16:40 |
III-21 Marcus Björnsson A population PK/PD model for bispectral index of the fast acting anesthetic AZD3043 in healthy volunteers Thursday 10:05-11:35 |
III-24 Irina Bondareva Population Pharmacokinetics of Phenytoin Estimated from Repeated Therapeutic Drug Monitoring (TDM) Data of Epileptic Patients Thursday 10:05-11:35 |
III-63 Farkad Ezzet Power Calculation Based on Pharmacokinetic Sampling Designs of ELND005 in a Phase 3 Clinical Trial Design in Mild Alzheimer Disease Patients Thursday 10:05-11:35 |
IV-16 Sophie Glatt A population pharmacokinetic analysis and pharmacokinetic/adverse events analysis of a sodium channel blocker in healthy subjects. Thursday 15:00-16:30 |
IV-17 Martin Gnanamuthu Johnson Title: Pharmacokinetic-Pharmacodynamic Modeling of the relationship between D2 receptor occupancy and Catalepsy in Rats: Predicting Extrapyramidal Side Effects in Humans Thursday 15:00-16:30 |
IV-25 Zheng Guan Population PK/PD modeling to compare cannabinoid receptor antagonists in the THC challenge test Thursday 15:00-16:30 |
IV-27 Monia Guidi Population Pharmacokinetics of Risperidone and 9-hydroxy-risperidone in psychiatric patients. Thursday 15:00-16:30 |
IV-44 Candice Jamois Pharmacokinetic-Receptor Occupancy Modeling to support Phase 2 Dose Selection Thursday 15:00-16:30 |
IV-46 Juliette Janson Population PKPD Modeling of BACE1 Inhibitor-Induced Reduction in Aβ Levels in vivo. Thursday 15:00-16:30 |
IV-53 Tatiana Karelina Kinetic Model of Amyloid Beta Distribution and Allometric Scaling from Mouse to Monkey and Human Thursday 15:00-16:30 |
IV-59 Magdalena Kozielska Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia Thursday 15:00-16:30 |